NCT01994473View on ClinicalTrials.gov

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

SEP-363856

SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg

DRUG

Placebo

single oral dose placebo

DRUG

SEP-363856 Open Label

75 mg SEP-363856 given once-daily

Trial Locations (2)

90806

Collaborative Neuroscience Network, LLC, Long Beach

91206

California Clinical Trials Medical Group, Glendale

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01994473 - Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter